Déborah Bauer

S174 Reduction of exacerbations according to type 2 inflammatory biomarkers with dupilumab treatment in patients with chronic obstructive pulmonary disease

Simon Couillard, Sanjay Ramakrishnan, Ian Pavord, Yunus Çolak et autres

Purpose In BOREAS and NOTUS, add-on dupilumab reduced moderate-or-severe exacerbation rates and improved lung function in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation. This post hoc analysis explored the predictive value of baseline blood eosinophil counts and fractional …

ca, au, gb, dk, de, fr, us (code pays fourni par la source)

REDUCTION OF EXACERBATIONS ACCORDING TO TYPE 2 INFLAMMATORY BIOMARKERS WITH DUPILUMAB TREATMENT IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Simon Couillard, Sanjay Ramakrishnan, Ian Pavord, Roland Buhl et autres

Reduction of Exacerbations According to Type 2 Inflammatory Biomarkers With Dupilumab Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Simon Couillard, Sanjay Ramakrishnan, Ian Pavord, Yunus Çolak et autres

Abstract RATIONALE: Type 2 (T2) inflammatory biomarkers, such as blood eosinophil counts (BEC) or fractional exhaled nitric oxide (FeNO) may help to predict response to therapy. Dupilumab, a human monoclonal antibody, blocks interleukin-4/13 signaling, key and central drivers of T2 inflammation. In …

ca, au, gb, dk, de, fr, us (code pays fourni par la source)

The C. elegans glutamate transporters GLT-4 and GLT-5 regulate protein expression, behavior, and lifespan

Grace J Bronstone, Moriah Harton, Maya Muldowney, James Reigle et autres

Glutamate transporters are important for regulating extracellular glutamate levels, impacting neural function and metabolic homeostasis. This study explores the behavioral, lifespan, and proteomic profiles in Caenorhabditis elegans strains with either glt-4 or glt-5 null mutations, highlighting contrasting phenotypes. Δ glt-4 mutants displayed …

us (code pays fourni par la source)

Treatment with dupilumab improved quality of life in patients with moderate-to-severe chronic obstructive pulmonary disease and type 2 inflammation: Phase 3 BOREAS trial

Alberto Papi, Ronald Mudry, S.P. Bhatt, Klaus F. Rabe et autres

it, fr, us, de, gb (code pays fourni par la source)

Dupilumab Efficacy and Safety in Patients with Moderate-to-Severe COPD with Type 2 Inflammation: Pooled Analysis of BOREAS and NOTUS Trials

Shweta Bhatt, A Hoheisel, Klaus F. Rabe, NA Hanania et autres

Introduction: BOREAS (NCT03930732) and NOTUS (NCT04456673), 52-week, phase 3, randomized, double-blind, placebo-controlled trials demonstrating dupilumab efficacy and safety data in patients with COPD. Objective: To evaluate the safety and efficacy of dupilumab in a pooled analysis combining both BOREAS and NOTUS. Methods: …

us, de, gb, it (code pays fourni par la source)

Dupilumab Improves Health-Related Quality of Life in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation: Pooled Boreas and Notus Results

Shweta Bhatt, Benjamin Waschki, Klaus F. Rabe, NA Hanania et autres

Purpose: Impaired quality of life contributes significantly to morbidity in chronic obstructive pulmonary disease (COPD). St. George’s Respiratory Questionnaire (SGRQ) is a patient-reported outcome measure of health-related quality of life (HRQoL) in respiratory disease. Methods: BOREAS (NCT03930732) and NOTUS (NCT04456673) were phase …

us, de, gb, it (code pays fourni par la source)

Dupilumab Improves Signs And Symptoms Of Chronic Spontaneous Urticaria Regardless Of Baseline Body Mass Index

Thomas B. Casale, Marcus Maurer, Ana M. Giménez‐Arnau, Sarbjit S. Saini et autres

Dupilumab significantly improves itch and hives in patients with chronic spontaneous urticaria (CUPID study C)

T. Casale, Sarbjit S. Saini, Jonine L. Bernstein, Ana M. Giménez‐Arnau et autres

us (code pays fourni par la source)

S93 Phase 3 NOTUS trial: dupilumab efficacy and safety in patients with moderate-to-severe chronic obstructive pulmonary disease and type 2 inflammation

Surya Prakash Bhatt, Klaus F. Rabe, NA Hanania, C. Franz Vogelmeier et autres

Introduction Patients with type 2 inflammation in COPD suffer from frequent exacerbations and high symptom burden. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component of interleukin (IL)-4 and IL-13, key and central drivers of type 2 inflammation. The second …

us, de, gb, it (code pays fourni par la source)

Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)

Surya P. Bhatt, Klaus F. Rabe, Nicola A. Hanania, Claus Vogelmeier et autres

Background Dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, reduced exacerbations and improved lung function in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation in the phase 3 BOREAS trial. Objective …

us, de, gb, it (code pays fourni par la source)

DUPILUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: THE PHASE 3 NOTUS TRIAL

SURYA P BHATT, KLAUS F RABE, Nicola A. Hanania, Claus Vogelmeier et autres